Filing summary
Identity note: The request identifies Axe Compute Inc., but the supplied Form 10-Q is for Predictive Oncology Inc. (Nasdaq: POAI). This summary covers the filing actually provided.
Business context and reporting period
Unaudited results are for the three months ended March 31, 2021, compared with the three months ended March 31, 2020. Predictive Oncology operates in precision medicine and clinical/CRO services (Helomics), protein solubility and stability services (Soluble), and medical fluid-disposal devices and supplies (Skyline). Management said it plans to focus resources on Helomics and precision medicine and drug discovery.
Financial results and liquidity
| Metric | Q1 2021 | Q1 2020 / prior balance |
|---|---|---|
| Revenue | $280,317 | $294,943 |
| Gross profit / margin | $182,559 / approximately 65% | $202,286 / approximately 69% |
| Operating loss | $3,777,671 | $3,439,352 |
| Net loss | $3,888,713 | $4,529,317 |
| Basic and diluted loss per share | $0.11 | $0.93 |
| Cash used in operations | $3,322,091 | $2,972,981 |
| Cash and cash equivalents | $27,299,407 | $678,332 at Dec. 31, 2020 |
| Total assets | $39,653,844 | $13,060,436 at Dec. 31, 2020 |
| Total liabilities | $4,108,757 | $10,417,755 at Dec. 31, 2020 |
| Notes payable | $0 | $4,431,925 net at Dec. 31, 2020 |
Financing cash inflows of $30.3 million included $31.1 million net proceeds from equity offerings and $4.5 million from warrant exercises, partly offset by $4.2 million of debt repayment and a $1.1 million payment premium. The company used $5.9 million of offering proceeds on March 1, 2021 to repay remaining principal, interest, and premiums on its 2018, 2019, and 2020 loans. Investing cash use was $393,121, primarily for fixed assets.
Material changes versus the prior period
- Revenue declined $14,626, or about 5%. Skyline remained the principal revenue source; the company sold a net three STREAMWAY units versus five a year earlier.
- Gross margin fell from approximately 69% to 65%; Skyline’s margin, excluding Helomics, fell from approximately 77% to 71%.
- Operating loss widened by approximately $338,000, as higher general and administrative and operations expenses more than offset lower sales and marketing costs. Net loss improved, primarily alongside substantially lower other expense than in Q1 2020.
- Cash rose sharply following equity fundraising. Common shares outstanding increased from 19.8 million at year-end to 48.8 million at March 31. The company also reported 15.1 million warrants outstanding at quarter-end.
- Management changes included J. Melville Engle’s appointment as CEO on March 19, 2021, following Carl Schwartz’s resignation.
Outlook, risks, and unusual items
- Management said existing capital resources were expected to support its operating plan at least through June 30, 2022. It also warned that additional capital may be needed and could be dilutive or carry onerous terms. At March 31, $9.8 million remained available under a three-year equity line, subject to market and other conditions; 572,504 shares were subsequently issued under the line through April 14.
- The company has a history of losses, negative operating cash flow, and revenue insufficient to fund operations. Management cautioned that it may not be able to continue operating past June 2022 without additional financing.
- COVID-19 had disrupted a STREAMWAY contract manufacturer, delayed parts and production, reduced on-site staffing and sales access, and affected collections and supplier payment demands. Management said further adverse effects remained possible.
- Disclosure controls and procedures were deemed ineffective at March 31 because of a material weakness: insufficient accounting resources with adequate expertise to identify and account for complex transactions. Remediation steps were underway, but management had not concluded the weakness was fully remediated.
- Q1 included $403,721 of stock-compensation expense related to modification of the restricted-share agreement and accelerated vesting in connection with the CEO’s retirement. The filing also reports a $95,671 gain on derivative instruments.
- Risks include continuing operating losses, future financing and dilution, possible goodwill impairment, competition, regulatory and intellectual-property issues, dependence on key personnel, and the ongoing effects of COVID-19. No legal proceedings were reported.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Predictive Oncology Inc., not Axe Compute Inc.
- Review cash burn and the assumptions behind management’s runway estimate through June 30, 2022.
- Assess dilution from the Q1 offerings, warrant exercises, outstanding warrants, and remaining equity-line availability.
- Track whether Helomics and Soluble generate meaningful revenue growth; Q1 total revenue remained below $0.3 million.
- Check subsequent filings for remediation of the material weakness and any changes to financing needs, liquidity, or COVID-related operating disruptions.